1. |
Parissis JT, Rafouli-Stergiou P, Paraskevaidis I, et al. Levosimendan:from basic science to clinical practice. J Heart Fail Rev, 2009, 14(4):265-275.
|
2. |
Antila S, Sundberg S, Lehtonen LA. Clinical pharmacology of levosimendan. J Clin Pharmacokinet, 2007, 46(7):535-552.
|
3. |
Kamath SR, Jaykumar I, Matha S. Levosimendan. J Indian Pediatr, 2009, 46(7):593-596.
|
4. |
Barilla F, Giordano F, Jacomelli I, et al. ST-segment elevation during levosimendan infusion. J Cardiovasc Med (Hagerstown), 2012, 13(7):454-456.
|
5. |
刘洋, 张静.左西孟旦治疗慢性心衰急性加重期患者的疗效观察.山东医药, 2011, 51(45):104.
|
6. |
王雷, 崔亮, 魏嘉平, 等.静脉注射左西孟旦治疗重度失代偿性心力衰竭患者的疗效分析.中华心血管病杂志, 2010, 6(38):527-530.
|
7. |
张明惠, 杜新平, 李玉芬.左西孟旦在难治性心力衰竭中的应用.山东医药, 2012, 52(1):76-77.
|
8. |
陈桂荣, 谢世全, 韩瑞鸿.钙增敏剂左西孟旦的研究新进展.辽宁中医药大学学报, 2011, 13(3):198-199.
|
9. |
Baba Y, Kuto T, Kitaoka H, et al. Usefulness of high-sensitive cardiac troponin T for evaluating the activity of cardiac sarcoidosis. J Int Heart J, 2012, 53(5):287-292.
|
10. |
Giannitsis E, Katus HA. Biomarkers:Pros and cons of highsensitivity assays for cardiac troponin. J Nat Rev Cardiol, 2012, 9(11):616-618.
|
11. |
Nieminen M. Levosimendan in patients with lef heart failure afer acute myocardial infarction-review of the russlan study and future developments with levosimenda. J Fur Kardiologie, 2011, 9(10):45-48.
|
12. |
Gollapudi S, Mamidi R, Mallampalli L, et al. The N-terminal extension of cardiac troponin T stabilizes the blocked state of cardiac thin flament. J Biophys J, 2012, 103(5):940-948.
|
13. |
毛懿, 杨宏, 张炜, 等.急性失代偿充血性心力衰竭患者氨基端脑钠肽前体水平与血流动力学参数间的相关性分析.中华老年多器官疾病杂志, 2012, 11(1):46-49.
|
14. |
李元建, 主编.药理学.北京:高等教育出版社, 2008. 169.
|
15. |
阙俐.左西孟旦治疗急性心衰的发展前景.国外医药(合成药生化药制剂分册), 2000, 21(6):370-371.
|
16. |
中华医学会心血管病学分会, 中华心血管病杂志编辑委员会.慢性心力衰竭诊断治疗指南.中华心血管病杂志, 2007, 35(12):1076-1094.
|
17. |
纪木火, 李仁奇, 张庆伟, 等, 钙增敏剂左西孟旦的研究进展.药学与临床研究, 2010, 18(5):23-24.
|
18. |
周占林, 徐坚, 王宁夫, 等.心肺运动试验对冠心病的诊断价值.[2009]年钱江国际心血管病会议暨浙江省心血管年会论文汇编, 2009. 55-57.
|
19. |
Fotbolcu H, Duman D. A promising new inotrope:levosimenda. J Anadolu Kardiyol Derg, 2010, 10(2):176-182.
|
20. |
Gui J, Yue Y, Chen R, et al. A20(TNFAIP3) alleviates CVB3-induced myocarditis via inhibiting NF-kappa B signaling. PLoS One, 2012, 7(9):e46515.
|